Acroscell Released iPSC-derived Cardiomyocytes to Accelerate General Cardiovascular Research

 Breaking News
  • No posts were found

Acroscell Released iPSC-derived Cardiomyocytes to Accelerate General Cardiovascular Research

May 01
00:23 2021
Acroscell announced the release of its iPSC-derived cardiomyocytes in order to accelerate general cardiovascular research.

New York, USA – April 30, 2021 – Acroscell, the mature branch of Creative Bioarray, a leading global provider of high quality services in research and development, Creative Bioarray provides cardiac and neuronal safety analysis and translational analysis for the academic, pharmaceutical and biotechnology industries. Recently, Acroscell announced the release of its iPSC-derived cardiomyocytes in order to accelerate general cardiovascular research.

Cardiomyocytes (also known as cardiomyocytes or cardiomyocytes) are the muscle cells (myocytes) that make up the heart muscle. Due to the lack of a natural source of heart cells, human cardiomyocytes differentiated in vitro have proved to be important tools not only for general cardiovascular research, but also for drug development and preclinical research.

As a service company with a strong presence in electrophysiological technologies, Acroscell focuses on in vivo and in vitro analysis. Based on the advanced electrophysiological screening platform, a variety of standard and customized drug safety and pharmacological testing methods and panels for drug screening and analysis are available. The Acroscell team has extensive drug discovery capabilities, expertise, and proven experience to successfully meet various project goals in delivering high quality data and on-time performance. Extensive global service capabilities and decades of experience in providing drug discovery services enable high quality, reproducible research performance with minimal repetition and high customer satisfaction.

In addition to drug screening tests (ion channels, GPCR receptors, and other exchangers and transporters, among others), Acroscell provides assayed that reveal specific abnormalities in many genetic models of cardiovascular and brain disease in humans, as well as the effects of new molecules on human function. The experiments shed light on new treatments and insights into the mechanisms of disease. From single-channel analysis to animal movement, Acroscell addresses all customer needs in electrophysiological analysis.

From target screening, cell function testing to animal behavior analysis, we provide our clients with comprehensive research at every step of the way in drug discovery research. Acroscell can provide strong support for customers’ preclinical studies to accelerate drug development and improve the quality of research.

“Creative Bioarray has a comprehensive cell library with a variety of specialized and unique stable cell line expression ion channels for immediate application in a variety of in vitro and in vivo pharmacological studies.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Creative Bioarray provides project consulting for preclinical studies to assist you in project management and execution. We are committed to helping you achieve your goals in drug development of the highest quality.”

About Acroscell

As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://acroscell.creative-bioarray.com

Categories